Go to the list of all blogs
John Y White's Avatar
published in Blogs
Oct 06, 2026
CLSK vs IREN: Two Bitcoin Miners Charting Distinct Routes into AI Infrastructure

CLSK vs IREN: Two Bitcoin Miners Charting Distinct Routes into AI Infrastructure

Key Takeaways

  • CLSK and IREN are both former Bitcoin miners now pivoting toward artificial intelligence (AI) and high-performance computing (HPC) data centers, but they are executing that transition in very different ways.
  • CLSK is anchoring its shift around long-duration lease revenue, headlined by a 20-year, $6.6 billion data center agreement.
  • IREN is moving further into a vertically integrated AI cloud model, where AI Cloud Services revenue has already overtaken Bitcoin mining revenue.
  • Both companies are carrying heavy near-term losses and capital requirements, making execution risk a central consideration for investors.
  • Relative performance and valuation differ sharply: IREN trades at a materially larger market capitalization and richer sales multiple than CLSK.

Setting the Stage for Two Digital Infrastructure Plays

CleanSpark and IREN Limited stand out as closely followed names in the shift from Bitcoin mining to AI and HPC data centers. This comparison matters for investors weighing how the same industry move is creating two separate business models and risk profiles. In my view, CLSK is tilting toward real-estate-style lease economics, while IREN is building an integrated AI cloud platform. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Grasping the differences in positioning, revenue mix, and capital needs can help assess which path aligns better with individual risk tolerance.

CLSK: Focusing on Long-Term Lease Revenue

CleanSpark has operated as one of the larger U.S. Bitcoin miners, yet recent activity shows a clear move into digital infrastructure and data center development. The standout event was the signing of a 20-year triple-net lease for its Sandersville, Georgia campus, expected to bring in roughly $6.6 billion in contracted revenue (and up to $11.6 billion with extensions) from a high-investment-grade technology tenant. The company reports about 1.8 gigawatts of contracted capacity along with a multi-gigawatt development pipeline. I’m watching this closely because the pivot has not yet fully offset Bitcoin-related pressures. Revenue declined year over year, and sizable net losses include non-cash mark-to-market charges on Bitcoin holdings. To support the Sandersville project, CLSK completed a $2.276 billion senior secured notes offering. Sentiment has turned more positive as investors balance the appeal of recurring data center revenue against ongoing Bitcoin price volatility and execution risks.

IREN: Building an Integrated AI Cloud Platform

IREN Limited (formerly Iris Energy) is shifting more aggressively from Bitcoin mining to a vertically integrated AI cloud platform that includes data centers, GPUs, and software. In its latest reported quarter, AI Cloud Services revenue exceeded Bitcoin mining revenue for the first time, marking a notable change in narrative. IREN reports roughly $4 billion in contracted annualized run-rate revenue, with about $1 billion already operating, and has secured multi-year deals with customers including Microsoft and NVIDIA. The transition involves costs, including decommissioning mining hardware ahead of GPU installations, with mining operations expected to wind down by the end of 2026. This has led to large non-cash impairments and a substantial full-year net loss. The company has raised billions in GPU financing and guides to a sizable capital-spending program, highlighting both the opportunity and the funding risks. Shares have recovered from a post-earnings dip as focus turns to the contracted AI backlog.

Head-to-Head: Contrasting Models and Risks

The main difference lies in the type of AI exposure. CLSK is pursuing a capital-light leasing approach, using its land and power assets through long-duration, triple-net contracts that pass operating costs to tenants and target high-margin, steady income. IREN is taking a capital-intensive integrated cloud route, owning and operating GPUs to capture more value per megawatt while shouldering greater build-out and financing demands. On growth, IREN is already generating AI revenue, whereas CLSK does not expect deliveries from its flagship lease until late 2027. Both remain sensitive to Bitcoin prices until their transitions finish, but CLSK keeps more near-term mining revenue while IREN is exiting mining faster. Valuation stands out as well: IREN has a substantially larger market capitalization and higher forward price-to-sales multiple, reflecting expectations around its AI backlog, whereas CLSK trades at a lower valuation with a longer runway before contracted revenue turns into cash flow.

Exploring AI Tools for Portfolio Insights

From what I see, tools like Tickeron’s AI Trend Prediction Engine help surface patterns across volatile names such as these two. I have used it in my own reviews to gauge momentum signals alongside fundamental shifts. It offers a practical way to layer quantitative views on top of the qualitative differences in their AI transitions without replacing core due diligence.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CLSK, IREN

Contributor

John Y White's AvatarJohn Y White|Beginner

Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active&section=trades&via=john


CLSK in +4.63% Uptrend, advancing for three consecutive days on September 22, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CLSK advanced for three days, in 233 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for CLSK crossed bullishly above the 50-day moving average on September 17, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.

The Aroon Indicator entered an Uptrend today. In 149 of 175 cases where CLSK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLSK as a result. In 70 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

The Moving Average Convergence Divergence Histogram (MACD) for CLSK turned negative on September 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 36 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

CLSK moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLSK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. CLSK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.500) is normal, around the industry mean (4.351). P/E Ratio (7.375) is within average values for comparable stocks, (30.023). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (0.809). Dividend Yield (0.000) settles around the average of (0.016) among similar stocks. P/S Ratio (5.397) is also within normal values, averaging (16.763).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLSK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.

Notable companies

The most notable companies in this group are Morgan Stanley (NYSE:MS), Goldman Sachs Group (NYSE:GS), Charles Schwab Corp (The) (NYSE:SCHW), Gold.com Inc. (NYSE:GOLD).

Industry description

These banks specialize in underwriting (helping companies with debt financing or equity issuances), IPOs, facilitating mergers and other corporate reorganizations and acting as a broker or financial advisor for institutions. They might also trade securities on their own accounts. Investment banks potentially thrive on expanding its network of clients, since that could help them increase profits. Goldman Sachs, Morgan Stanley and CME Group Inc are some of the largest investment banking companies.

Market Cap

The average market capitalization across the Investment Banks/Brokers Industry is 12.69B. The market cap for tickers in the group ranges from 590 to 304.12B. MS holds the highest valuation in this group at 304.12B. The lowest valued company is FSSLD at 590.

High and low price notable news

The average weekly price growth across all stocks in the Investment Banks/Brokers Industry was 1%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was 4%. XP experienced the highest price growth at 39%, while PMAX experienced the biggest fall at -35%.

Volume

The average weekly volume growth across all stocks in the Investment Banks/Brokers Industry was 12%. For the same stocks of the Industry, the average monthly volume growth was -6% and the average quarterly volume growth was -50%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 66
P/E Growth Rating: 63
Price Growth Rating: 59
SMR Rating: 74
Profit Risk Rating: 86
Seasonality Score: 24 (-100 ... +100)
View a ticker or compare two or three
CLSK
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which offers advanced energy software and control technology that enables a plug-and-play enterprise solution to modern energy challenges.

Industry InvestmentBanksBrokers

Industry
N/A
Address
10624 South Eastern Avenue
Phone
+1 702 989-7692
Employees
314
Web
https://www.cleanspark.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
GE Aerospace (GE) stock declined -12% over the past 30 days, falling from around $333 to $293, amid profit-taking after record highs near $348. Over the past quarter, the stock is down -8%, reflecting post-earnings selloff despite strong Q4 2025 results with 20% revenue growth.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
NBR stock rose approximately +12% over the last 30 days, driven by positive momentum in the oil and gas drilling sector and strong Q4 earnings beat. Over the past quarter, the stock surged +58%, fueled by robust YTD performance, debt reduction efforts, and improved operational results in international drilling.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.